Brind.

The FDA approved Linvoseltamab for the treatment of multiple myeloma, a drug developed by Regeneron Pharmaceuticals.

1 report, 1 independent Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The FDA approved Linvoseltamab for the treatment of multiple myeloma, a drug developed by Regeneron Pharmaceuticals.

Who's involved

What this event is mainly about
FDARegeneron Pharmaceuticals

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Insider MonkeyFDA Approves Regeneron Pharmaceuticals, Inc. (REGN)’s Linvoseltamab for Multiple Myeloma We recently published 11 Best Cancer Stocks to Buy Right Now. Regeneron Pharmaceuticals, Inc. is placed second